Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 282-287

  Pfaller, Michael A ^a   Castanheira, Mariana ^b   Sader, Helio S ^b   Jones, Ronald N ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b JMI LABORATORIES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fusidic acid; North America; Staphylococci; Surveillance

Indexed keywords

CEM 102; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; NEOMYCIN; OXACILLIN; PENICILLIN G; PSEUDOMONIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CANADA; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; FUSIDIC ACID; HUMANS; MICROBIAL SENSITIVITY TESTS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS; UNITED STATES;

EID: 73549115374     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.10.023     Document Type: Article

References (15)

1. Cornaglia G., and Rossolini G.M. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect 15 (2009) 218-223
2. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., and Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 52 (2008) 2244-2246
3. Falagas M.E., and Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 13 (2007) 592-597
4. Anderson J.D. Fusidic acid: new opportunities with an old antibiotic. Can Med Assoc J 122 (1980) 765-769
5. Howden B.P., and Grayson M.L. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42 (2006) 394-400
6. Dobie D., and Gray J. Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 89 (2004) 74-77
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2009.
9. Pfaller M.A., Jones R.N., Doern G.V., and Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 42 (1998) 1762-1770
10. McLaws F., Chopra I., and O'Neill A.J. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J Antimicrob Chemother 61 (2008) 1040-1043
11. Laurent F., Tristan A., Croze M., Bes M., Meugnier H., Lina G., et al. Presence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus in France. J Antimicrob Chemother 63 (2009) 420-421
12. O'Neill A.J., Larsen A.R., Skov R., Henriksen A.S., and Chopra I. Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol 45 (2007) 1505-1510
13. Sule O., Brown N.M., Willocks L.J., Day J., Shankar S., Palmer C.R., et al. Fusidic acid-resistant Staphylococcus aureus (FRSA) carriage in patients with atopic eczema and pattern of prior topical fusidic acid use. Int J Antimicrob Agents 30 (2007) 78-82
14. Tveten Y., Jenkins A., and Kristiansen B.E. A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in Norway. J Antimicrob Chemother 50 (2002) 873-876
15. Rennie R.P. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg 10 (2006) 277-280